Biotech Values

[jmkobers]

I dont have the post #, but I believe you also stated that if both MNTA and TEVA got their lovenox approvals, MNTA's share price would probably go DOWN due to the way the split % is derived under the multiple approval scenario, and that is when the stock price was in the 11-13 dollar range. IIRC, MNTA revenue with multiple approvals for lovenox would be in the neighborhood of 50 million annually.

TEVA's approval could come in any time and would send MNTA's pps diving, especially considering the current trading price. The uncertainty of the TEVA ANDA is what will keep the valuation reasonable and it should give caution to those who think it is a gift here.